This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve

 

 

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK ( TheStreet) -- The Federal Reserve is run by intelligent people after all, Jim Cramer said Wednesday. He told his Mad Money viewers they should stop worrying and start thinking about how to make more money.

Cramer said the Fed is doing the right thing, making judgments based on the facts and not on what the market pundits are expecting. Fed Chair Janet Yellen admitted that interest rates are being kept lower for longer than the central bank would like, but that's what's required given the aftermath of the Great Recession.

Read More: 10 Stocks George Soros Is Buying

Cramer called this common-sense approach to central banking "refreshing," but admitted that it drives money managers bonkers as they can't be exactly sure what's coming next. But while these same managers charge that the Fed is "behind the curve," in actuality they just don't understand the plight of real families or that companies just aren't hiring the way they were before.

Cramer said the stigma of the Great Recession is not unlike what our grandparents had for the Great Depression. Many of our grandparents were scarred for life from those events, he noted, and many never invested in the markets again. That's why this time the Fed wants to be absolutely certain things are moving swiftly before it intervenes.

One day the pain of the Great Recession will be a distant memory, Cramer concluded. Until then, the Fed is likely to stay the course.

Executive Decision: Stanley Crooke

For his "Executive Decision" segment, Cramer spoke with Dr. Stanley Crooke, chairman, president and CEO of Isis Pharmaceuticals (ISIS) , a biotech with 32 drugs under development. Shares of Isis are up 47% since Cramer last checked in back in May and a staggering 336% since Cramer first recommended the stock two and a half years ago.

Crooke admitted that Isis is a complicated story as the company has both orphan drugs and mass market drugs under development. He said that investors should focus on both sides of the business because Isis' platform allows the company to have a growing pipeline of applications.

When asked about those applications, Crooke noted Isis' strength is in its efficiency. He said the company only has 400 employees yet is able to have 32 drugs currently under development. That leads to a tremendous advantage and why companies like AstraZeneca (AAZN) are partners and collaborators with Isis.

Read More: Here Are Five Takeaways From Janet Yellen's Press Conference

Cramer said that with so many exciting drugs under development, Isis remains a compelling investment story, even if it may be complicated to figure out.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs